HIMS

HIMS

USD

Hims & Hers Health Inc. Class A Common Stock

$44.070-1.680 (-3.672%)

السعر في الوقت الحقيقي

Healthcare
Drug Manufacturers - Specialty & Generic
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$45.750

الأعلى

$48.340

الأدنى

$43.620

الحجم

36.16M

أساسيات الشركة

القيمة السوقية

10.0B

الصناعة

Drug Manufacturers - Specialty & Generic

البلد

United States

إحصاءات التداول

متوسط الحجم

28.91M

البورصة

NYQ

العملة

USD

نطاق 52 أسبوعاً

الأدنى $19.15الحالي $44.070الأعلى $72.98

أخبار ذات صلة

Analyst Upgrades

B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32

B of A Securities analyst Allen Lutz maintains Hims & Hers Health with a Underperform and raises the price target from $28 to $32.

عرض المزيد
B of A Securities Maintains Underperform on Hims & Hers Health, Raises Price Target to $32
Reuters

Futures tumble after Wall St banks warn of market pullback, Palantir slides

U.S. stock futures tumbled on Tuesday as investors questioned lofty valuations in the technology sector after top Wall Street banks warned of a stock market selloff and AI darling Palantir's sales forecast failed to lift the mood.

عرض المزيد
Futures tumble after Wall St banks warn of market pullback, Palantir slides
Analyst Upgrades

BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target

BTIG analyst David Larsen reiterates Hims & Hers Health with a Buy and maintains $85 price target.

عرض المزيد
BTIG Reiterates Buy on Hims & Hers Health, Maintains $85 Price Target
Reuters

Hims and Hers beats revenue estimates on strong subscriber growth

Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings.

عرض المزيد
Hims and Hers beats revenue estimates on strong subscriber growth
BusinessWire

Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results

Revenue of nearly $600 million, up 49% year-over-year in Q3 2025 Net income of nearly $16 million; Adjusted EBITDA of over $78 million in Q3 2025 Subscribers grew to almost 2.5 million, up 21% year-over-year in Q3

عرض المزيد
Hims & Hers Health, Inc. Reports Third Quarter 2025 Financial Results
PR Newswire

LEVI & KORSINSKY ISSUES CORRECTION: Securities Fraud Class Action Against Hims & Hers Health, Inc.

A securities fraud class action lawsuit against Hims & Hers Health, Inc. (NYSE: HIMS) is pending. The lawsuit was filed by Glancy Prongay & Murray...

Analyst Upgrades

Keybanc Initiates Coverage On Hims & Hers Health with Sector Weight Rating

Keybanc analyst Justin Patterson initiates coverage on Hims & Hers Health with a Sector Weight rating.

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.